相关实验视频

Updated: Jun 29, 2025

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye

Published on: August 16, 2014

基因组编辑 VEGFA 在活体中防止角膜新血管化

Zhenhai Zeng^1,2, Siheng Li^1,3, Xiuhong Ye⁴

¹Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, 200000, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|April 6, 2024

概括

使用CRISPR/Cas9的基因编辑有效地抑制血管内皮生长因子A (VEGF-A),以治疗角膜新血管化 (CNV). 这种新的方法为各种眼部疾病提供了一个有前途的治疗策略.

科学领域:

眼科医生眼科眼科
分子生物学分子生物学
基因治疗基因治疗

背景情况:

角膜新血管化 (CNV) 是视力丧失的一个重要原因.
目前针对血管内皮生长因子A (VEGF-A) 的血管内皮生长因子A (VEGF-A) 的治疗方法存在局限性和不良影响.
基因编辑为CNV提供了一个新的治疗途径.

研究的目的:

调查CRISPR/Cas9系统在抑制VEGFA治疗CNV中的有效性.
评估基因编辑作为角膜血管生成的治疗策略的潜力.

主要方法:

利用一种新的CRISPR/Cas9系统来准和消耗VEGFA.
在实验室中评估了VEGFA枯竭对人静脉内皮细胞 (HUVEC) 增殖,迁移和管形成的影响.
在一只小鼠模型中通过结诱导的CNV进行了双重AAV-SpCas9/sgRNA-VEGFA系统的子结膜注射.

主要成果:

使用CRISPR/Cas9系统的VEGFA枯竭在体外显著抑制了HUVEC的增殖,迁移和管形成.
在小鼠中,下注入CRISPR/Cas9系统有效地阻断了VEGFA,CD31和α-平滑肌肉动蛋白的结诱导表达.
在小鼠模型中,治疗成功抑制了角膜新血管化.

结论:

这项研究表明了CRISPR/Cas9介导的VEGFA基因编辑在治疗角膜新血管化的潜力.
这种基因编辑方法为CNV提供了一个有前途的新型治疗策略,有可能减少副作用.
这项研究为眼科中的基因编辑疗法建立了基础方法.

关键词:

(克里斯普尔) /Cas9 (克里斯普尔) /Cas9是什么意思在CNV中,NV是NV.在VEGFA中,VEGFA是VEGFA.基因组编辑基因组编辑

更多相关视频

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse

An Alkali-burn Injury Model of Corneal Neovascularization in the Mouse

Published on: April 7, 2014

In Vitro Model of Coronary Angiogenesis

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

相关概念视频

In-vitro Mutagenesis

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...